References to other published versions of this review Al-aqeel 2010 Sinaa Al-aqeel, Jawza Al-sabhan. Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy. Cochrane Database of Systematic Reviews 2010, Issue 1.

No abstract

No abstract

published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User

No abstract

Objectives: To measure psychiatrists’ experience and their expectations of the role of clinical pharmacists in Riyadh, Saudi Arabia. Subjects and Methods: The psychiatrists’ experience and their expectations were collected using a 4-part self-completed questionnaire: (a) demographic information, (b) psychiatrists’ current expectations of the roles of pharmacists, (c) psychiatrists’ actual experience with pharmacists, and (d) psychiatrists’ future expectations of pharmacists’ roles. Each part included a set of statements for which respondents were asked to indicate their level of agreement using a 5-point Likert scale. Results: Of the 102 questionnaires delivered to the Department of Psychiatry at 7 hospitals, 77 were returned, representing a response rate of 75%. 59 (77%) psychiatrists expected pharmacists to take personal responsibility for resolving any drug-related problems; 62 (81%) expected them to maintain a complete medication profile, and 58 (75%) expected them to educate patients about the safety and appropriate use of their medication. From their current experience with pharmacists, respondents indicated that pharmacists routinely counsel patients (33, 43%), inform them about the most cost-effective alternative (37, 48%), and discuss with them the therapeutic value of the drugs (37, 48%). 49 (63%) of respondents agreed that in the future, pharmacists should routinely adjust the drug therapy for patients under protocol approved by the physician, and 51 (66%) felt that pharmacists should share legal responsibility for clinical outcomes. Conclusion: Psychiatrists in Riyadh had great expectations of clinical pharmacists to take personal responsibility for resolving drug-related problems they discovered and to assist in designing drug therapy treatment plans. The psychiatrists’ current experience with pharmacists did not, in some cases, meet their expectations.

BackgroundAdvertising is a crucial component of pharmaceutical industry promotion. Research indicates that information on advertisement materials might be inadequate, inaccurate, biased, and misleading.ObjectiveTo analyse and critically assess the information presented in print pharmaceutical advertisements in Saudi Arabia.MethodsPharmaceutical advertisements were collected from 280 community pharmacies in Riyadh city, Saudi Arabia. The advertisements were evaluated using criteria derived from the Saudi Food and Drug Authority (SFDA) regulation, the World Health Organization (WHO) ethical medicinal drug promotion criteria, and other principles reported in similar studies. The data were extracted independently by two of the researchers using a standardized assessment form.ResultsOne hundred eighty five printed advertisements were included in the final sample. Approximately half of the advertisements (n = 94, 51%) were for over-the-counter (OTC) medications, and 71 (38%) were for prescription-only medication. Information such as the name of active ingredients was available in 168 (90.8%) advertisements, therapeutic uses were mentioned in 156 (98.7%) of analysed advertisements. Safety information related to side effects, precautions, and major interactions were stated in 53 (28.5%), 58 (31%), and 33 (16.5%) advertisements, respectively. Only 119 advertisements (64%) provided references for information presented.ConclusionsOur findings suggest that print advertisements do not convey all the information necessary for safe prescribing. These results have implications for the regulation of drug advertising and the continuing education of pharmacists.

From the perspective of repurposing medication, recent evidence suggests that the use of selective serotonin reuptake inhibitor antidepressants (SSRIs) can help reduce the severity of symptoms and death associated with SARS-CoV-2 infection. To focus more, COVID-19 is a viral disease with potentially high risk of symptoms. There is presently no cure. However, there are specific treatments that may help manage the condition. Since the SSRI fluvoxamine has a unique mechanism of action in reducing cytokine production, researchers have started to relate the antiviral effects via modulation of sigma-1 receptors with the vision of treatment options for COVID-19 patients. The scope of this chapter is to examine different mechanisms of fluvoxamine in relation to immune response, including both the serotonin and the sigma-1 receptor-related mechanisms. Addressing the impact of fluvoxamine in minimizing possible complications during COVID-19 infection.